{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:03:18Z","timestamp":1777356198410,"version":"3.51.4"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tmreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.tmrv.2016.07.002","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T12:45:36Z","timestamp":1469537136000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate"],"prefix":"10.1016","volume":"30","author":[{"given":"Rowena C.","family":"Punzalan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome L.","family":"Gottschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2016.07.002_bb0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-01-0047","article-title":"Developmental haemostasis. Impact for clinical haemostasis laboratories","volume":"95","author":"Monagle","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V70.1.165.165","article-title":"Development of the human coagulation system in the full-term infant","volume":"70","author":"Andrew","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V72.5.1651.1651","article-title":"Development of the human coagulation system in the healthy premature infant","volume":"72","author":"Andrew","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/trf.12322","article-title":"Reference intervals for common coagulation tests of preterm infants","volume":"54","author":"Christensen","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1055\/s-0031-1297164","article-title":"Pediatric hemophilia: a review","volume":"37","author":"Kulkarni","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0030","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1365-2516.2009.02074.x","article-title":"Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from the centers for disease control and prevention's (CDC) universal data collection (UDC) project","volume":"15","author":"Kulkarni","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0035","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1111\/hae.12310","article-title":"Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia a","volume":"20","author":"Steele","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2010.08545.x","article-title":"Guideline on the management of haemophilia in the fetus and neonate","volume":"154","author":"Chalmers","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0045","author":"Pfizer"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0050","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40265-015-0451-5","article-title":"New and emerging agents for the treatment of hemophilia: focus on extended half-life recombinant clotting proteins","volume":"75","author":"Ragni","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/17474086.2014.951322","article-title":"Alprolix (recombinant factor IX fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B","volume":"7","author":"Ducore","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0060","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1111\/jth.12912","article-title":"Longer-acting clotting factor concentrates for hemophilia","volume":"13","author":"Powell","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0065","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2014-07-580498","article-title":"Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2516.2010.02316.x","article-title":"Bleeding disorders in neonates","volume":"16","author":"Kenet","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood.V126.23.5.5","article-title":"Source of factor VIII replacement (PLASMATIC OR RECOMBINANT) and incidence of inhibitory alloantibodies in previously untreated patients with severe hemophilia A: the multicenter randomized sippet study","volume":"126","author":"Peyvandi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/hae.12479","article-title":"Incidence and risk factors for inhibitor development in previously untreated severe haemophilia a patients born between 2005 and 2010","volume":"20","author":"Vezina","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.12301","article-title":"Inhibitors in haemophilia: what have we learned from registries? A systematic review","volume":"277","author":"Osooli","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0033-1356715","article-title":"Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update","volume":"39","author":"Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0095","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/asheducation-2014.1.364","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"2014","author":"Kempton","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/hae.12574","article-title":"FEIBA in the treatment of acquired haemophilia a: results from the prospective multicentre French \u2018FEIBA dans l'hemophilie A acquise\u2019 (FEIBHAC) registry","volume":"21","author":"Borg","year":"2015","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.tmrv.2016.07.002_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004449.pub3","article-title":"Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors","author":"Iorio","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0115","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJMcibr1505657","article-title":"Targeting antithrombin to treat hemophilia","volume":"373","author":"Ragni","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0130","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.thromres.2012.08.299","article-title":"Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia","volume":"130","author":"Gissel","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0135","first-page":"ER60","article-title":"Intracranial hemorrhage in a term newborn with severe von Willebrand disease type 3 associated with sinus venous thrombosis","volume":"91","author":"Wetzstein","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00015559850135986","article-title":"Infantile acute haemorrhagic oedema in a child with von Willebrand's disease","volume":"78","author":"Ricci","year":"1998","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0145","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0150","author":"Novo Nordisk"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jpeds.2010.10.038","article-title":"Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study","volume":"158","author":"Witmer","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pbc.22053","article-title":"Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children","volume":"53","author":"Young","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MPH.0b013e318286d27e","article-title":"Predicting response to rFVIIa in neonates with intractable bleeding or severe coagulation disturbances","volume":"35","author":"Gkiougki","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.PCC.0000185491.17584.4B","article-title":"A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life","volume":"7","author":"Veldman","year":"2006","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0175","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/CIRCULATIONAHA.110.006304","article-title":"Risk, clinical features, and outcomes of thrombosis associated with pediatric cardiac surgery","volume":"124","author":"Manlhiot","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1213\/ANE.0b013e31825aff10","article-title":"Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients","volume":"115","author":"Guzzetta","year":"2012","journal-title":"Anesth Analg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0185","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mbc.0000233369.03358.c1","volume":"17","author":"Ekert","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0190","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.jvca.2011.05.012","article-title":"Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass","volume":"25","author":"Pychynska-Pokorska","year":"2011","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ajh.21046","article-title":"Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature","volume":"83","author":"Leissinger","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.blre.2008.06.001","article-title":"Vitamin K deficiency bleeding (VKDB) in early infancy","volume":"23","author":"Shearer","year":"2009","journal-title":"Blood Rev"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-2007-1000653","article-title":"Vitamin K deficiency bleeding in infants and children","volume":"21","author":"Sutor","year":"1995","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0210","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/14767058.2011.607677","article-title":"Clinical use of fresh-frozen plasma and cryoprecipitate in neonatal intensive care unit","volume":"24","author":"Motta","year":"2011","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0215","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jpeds.2015.09.030","article-title":"Prothrombin complex concentrate for intracerebral hemorrhage secondary to vitamin K deficiency bleeding in a 6-week-old child","volume":"167","author":"Rech","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0220","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0225","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2516.2008.01878.x","article-title":"Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency","volume":"15","author":"Bowles","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0230","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0140-6736(73)91297-X","article-title":"Intracranial haemorrhage in low-birth-weight infants and prophylactic administration of coagulation-factor concentrate","volume":"1","author":"Waltl","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0235","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5694\/j.1326-5377.1973.tb110804.x","article-title":"Prevention of intraventricular haemorrhage in babies receiving artificial ventilation","volume":"1","author":"Thomas","year":"1973","journal-title":"Med J Aust"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0240","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0049-3848(13)70018-5","article-title":"Intraventricular hemorrhage in preterm infants and coagulation\u2014ambivalent perspectives?","volume":"131","author":"Kuperman","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0245","series-title":"RiaSTAP package insert","year":"2009"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0250","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MBC.0000000000000086","article-title":"Congenital afibrinogenemia in a new born: a rare cause for bleeding","volume":"25","author":"Kaur","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0255","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2516.2004.00944.x","article-title":"The rare coagulation disorders\u2014review with guidelines for management from the United Kingdom Haemophilia Centre doctors' organisation","volume":"10","author":"Bolton-Maggs","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0260","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0038-1655952","article-title":"Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass","volume":"77","author":"Chan","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0265","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1213\/ANE.0b013e3181cd6d20","article-title":"The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children","volume":"110","author":"Moganasundram","year":"2010","journal-title":"Anesth Analg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0270","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/MBC.0b013e32836029d2","article-title":"Ex-vivo response to blood products and haemostatic agents after paediatric cardiac surgery","volume":"24","author":"Hvas","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MBC.0000000000000379","article-title":"Changes in thrombin generation in children after cardiac surgery and ex-vivo response to blood products and haemostatic agents","volume":"27","author":"Andreasen","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0280","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jtcvs.2014.07.022","article-title":"Fibrinogen concentrate as first-line therapy in children undergoing cardiac surgery: promising perspectives","volume":"149","author":"Faraoni","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0285","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MBC.0b013e32832da1c5","article-title":"Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (haemocomplettan P)","volume":"20","author":"Dickneite","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0290","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12185-014-1664-1","article-title":"Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency","volume":"100","author":"Naderi","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0300","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/j.thromres.2010.05.028","article-title":"Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study","volume":"126","author":"Ternstrom","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0305","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1160\/TH08-12-0826","article-title":"Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report","volume":"102","author":"Levy","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0310","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/tme.12069","article-title":"Thromboelastometric detection of clotting factor XIII deficiency in cardiac surgery patients","volume":"23","author":"Grossmann","year":"2013","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0315","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00246-014-0903-9","article-title":"Dynamics of factor XIII levels after open heart surgery for congenital heart defects: do cyanotic and acyanotic patients differ?","volume":"35","author":"Bockeria","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0320","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/pan.12193","article-title":"The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery","volume":"23","author":"Gertler","year":"2013","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0325","doi-asserted-by":"crossref","first-page":"13119","DOI":"10.1038\/srep13119","article-title":"Impaired activity of blood coagulant factor XIII in patients with necrotizing enterocolitis","volume":"5","author":"Tao","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0330","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1160\/TH08-10-0672","article-title":"Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update","volume":"101","author":"Rodgers","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0335","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1213\/ANE.0b013e31827e4e62","article-title":"Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass","volume":"116","author":"Finley","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0340","author":"Grifols"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0345","series-title":"Atryn (recombinant antithrombin) prescribing information","year":"2009"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0350","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jpeds.2013.06.036","article-title":"Antithrombin concentrate use in children: a multicenter cohort study","volume":"163","author":"Wong","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0355","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MAT.0b013e318279854a","article-title":"Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation","volume":"59","author":"Bembea","year":"2013","journal-title":"ASAIO J"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0360","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/PCC.0000000000000322","article-title":"Antithrombin concentrates use in children on extracorporeal membrane oxygenation: a retrospective cohort study","volume":"16","author":"Wong","year":"2015","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0365","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MAT.0000000000000204","article-title":"Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation","volume":"61","author":"O'Meara","year":"2015","journal-title":"ASAIO J"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0370","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0022-3476(96)70252-4","article-title":"Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants","volume":"129","author":"Urlesberger","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0375","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.jpedsurg.2012.11.037","article-title":"Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation","volume":"48","author":"Perry","year":"2013","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0380","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MAT.0000000000000010","article-title":"Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life","volume":"60","author":"Byrnes","year":"2014","journal-title":"ASAIO J"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0385","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1525-1594.2011.01384.x","article-title":"Antithrombin replacement during extracorporeal membrane oxygenation","volume":"35","author":"Niebler","year":"2011","journal-title":"Artif Organs"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0390","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/aor.12642","article-title":"A pilot study of antithrombin replacement prior to cardiopulmonary bypass in neonates","volume":"40","author":"Niebler","year":"2016","journal-title":"Artif Organs"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0395","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jtcvs.2015.10.003","article-title":"Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: impact of low antithrombin activity","volume":"151","author":"Manlhiot","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0400","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00000539-200101000-00013","article-title":"Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients","volume":"92","author":"Dietrich","year":"2001","journal-title":"Anesth Analg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0405","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.23607","article-title":"Hypercoagulability panel testing predicts thrombosis in neonates undergoing cardiac surgery","volume":"89","author":"Emani","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0410","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.thromres.2013.06.014","article-title":"Chylothorax in children with congenital heart disease: incidence of thrombosis","volume":"132","author":"Bauman","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0415","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0022-5223(96)70050-8","article-title":"Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations","volume":"112","author":"Petaja","year":"1996","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0420","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/PCC.0b013e3181c59032","article-title":"Study of protein C, protein S, and antithrombin III in newborns with sepsis","volume":"11","author":"El Beshlawy","year":"2010","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0425","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/(SICI)1096-8652(199609)53:1<18::AID-AJH4>3.0.CO;2-8","article-title":"High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children","volume":"53","author":"Fuse","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0430","first-page":"134","article-title":"[treatment of disseminated intravascular coagulation with antithrombin III concentrate in children with verified infection]","volume":"204","author":"Nowak-Gottl","year":"1992","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0435","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00451912","article-title":"Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation","volume":"144","author":"von Kries","year":"1985","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0440","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.PCC.0000113261.13338.C3","article-title":"Study of protein C, protein S, and antithrombin III in hypoxic newborns","volume":"5","author":"El Beshlawy","year":"2004","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005383.pub2","article-title":"Antithrombin for respiratory distress syndrome in preterm infants","volume":"4","author":"Bassler","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0450","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archpedi.1994.02170040055009","article-title":"Inherited antithrombin III deficiency in the neonate","volume":"148","author":"Seguin","year":"1994","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0455","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0049-3848(93)90127-A","article-title":"Congenital antithrombin III deficient neonate treated with antithrombin III concentrates","volume":"70","author":"Shiozaki","year":"1993","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0460","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jpeds.2015.06.006","article-title":"Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis","volume":"167","author":"Diaz","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0465","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/pbc.24899","article-title":"Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis","volume":"61","author":"Corder","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0470","unstructured":"Baxalta. CEPROTIN [protein C concentrate (human)] package insert; March 2007."},{"key":"10.1016\/j.tmrv.2016.07.002_bb0475","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/adc.2010.199919","article-title":"Purpura fulminans: recognition, diagnosis and management","volume":"96","author":"Chalmers","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0480","first-page":"51","article-title":"Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency","volume":"4","author":"Kroiss","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0485","first-page":"130","article-title":"[replacement therapy with protein C for meningococcal sepsis and fulminant purpura in pediatric patients]","volume":"28","author":"Llinares Tello","year":"2004","journal-title":"Farm Hosp"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0490","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1055\/s-2007-994962","article-title":"Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans","volume":"25","author":"Ettingshausen","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0495","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2007-1000658","article-title":"Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency","volume":"21","author":"Dreyfus","year":"1995","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0500","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjh.12640","article-title":"Subcutaneous protein C concentrate in the management of severe protein C deficiency\u2014experience from 12 centres","volume":"164","author":"Minford","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0505","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MBC.0000000000000079","article-title":"Continuous subcutaneous infusion of protein C concentrate using an insulin pump in a newborn with congenital protein C deficiency","volume":"25","author":"Piccini","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0510","doi-asserted-by":"crossref","first-page":"e1338","DOI":"10.1542\/peds.2009-2913","article-title":"Long-term subcutaneous protein C replacement in neonatal severe protein C deficiency","volume":"127","author":"de Kort","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0515","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/08880010490477365","article-title":"Subcutaneous administration of protein C concentrate","volume":"21","author":"Mathias","year":"2004","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0520","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1055\/s-0037-1614593","article-title":"Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate","volume":"81","author":"Sanz-Rodriguez","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0525","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1097\/00003246-200107001-00028","article-title":"Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation","volume":"29","author":"Levi","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0530","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1086\/319995","article-title":"Protein C replacement in severe meningococcemia: rationale and clinical experience","volume":"32","author":"Alberio","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0535","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0030-1254050","article-title":"Disseminated intravascular coagulation in term and preterm neonates","volume":"36","author":"Veldman","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0540","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00431-006-0139-7","article-title":"Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns","volume":"165","author":"Lauterbach","year":"2006","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0545","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/INF.0b013e3180f616f0","article-title":"Low plasma protein C values predict mortality in low birth weight neonates with septicemia","volume":"26","author":"Venkataseshan","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0550","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.PCC.0000217470.68764.36","article-title":"ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis","volume":"7","author":"Goldstein","year":"2006","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0555","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspectiVE (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0560","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SHK.0b013e3181e7623e","article-title":"Protein C concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: a pilot study","volume":"34","author":"Decembrino","year":"2010","journal-title":"Shock"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0565","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/j.1651-2227.2009.01404.x","article-title":"Protein C concentrate in preterm neonates with sepsis","volume":"98","author":"Fischer","year":"2009","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.tmrv.2016.07.002_bb0570","first-page":"29","article-title":"Use of protein C concentrate in neonatal period","volume":"62","author":"De Carolis","year":"2010","journal-title":"Minerva Pediatr"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796316300256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796316300256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T20:59:42Z","timestamp":1656881982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796316300256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0887796316300256"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2016.07.002","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2016.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}